Background: The study reviews the anticancer properties of natural isoflavones which occur in especially high concentration in soybeans. It considers the suitability of soybean products for clinical trials aiming to reduce the progression of breast cancer.
Introduction
Compelling evidence that fresh vegetables and fruit can protect against cancer was presented at a recent symposium of the American Association for Cancer Research in Washington [1] . Participants advised that second generation dietary supplement trials needed to be planned, even though the first group of vitamin and mineral studies are not yet completed. In the case of breast cancer, multiple reports have shown a decreased risk in association with a high dietary intake of vegetable or fruit fibre (reviewed in [2] ), but trials aiming to identify the specific protective agents are limited by the absence of a reliable molecular marker of early malignant change in breast tissue. One way forward is to test dietary supplements known to contain cancer-restraining agents in early breast cancer patients by long-term adjuvant treatment after primary surgery. Using a protocol similar to that used in the Milan vitamin A analogue trials [3] , delay in recurrence and reduction of second primary growths can be looked for.
Anticancer properties of isoflavones
Soybeans are rich in isoflavones which are converted in the bowel to compounds with antiproliferative properties. Soy fractions which contain genistein have been shown to inhibit the growth of various animal tumours including mammary, prostate, colon, bladder, liver, lung and skin cancers [4] . In the case of mammary tumours, genistein-containing soy fractions inhibit the growth of carcinogen-induced mammary cancer in both adult and prepubertal rats [5] . In addition, they inhibit the growth of additional tumours which often appear after excision of the primary mammary tumour [6] .
Isoflavones also exert a cytostatic effect on several cell lines derived from human mammary cancer [7] . Genistein is the most active of the isoflavones in this respect but daidzein and equol are also effective. In addition, other components of soy fractions, such as phytic acid and protease inhibitors have shown growthinhibitory properties [7] . While isoflavones are most abundant in legumes such as soybeans and chickpeas, they are also present in cereals, seeds, and fruits, and both naringenin and hesperetin found in oranges and grapefruit, have been shown to inhibit the growth of human breast cancer cell lines [8] .
Soy protein is present in more than half of Western supermarket food products and its use is increasing. Modern soy products are bland in flavour and are processed into chocolate, cooking oils, milk drinks, pasta, sausage, breakfast cereals, desserts and precooked meals, or sold as soy drinks, tofu, soy flour and soy flakes. In spite of this, the Westerner's intake of isoflavones is still less than 5 mg daily compared with 20 to 80 mg for Asians [7] . In Japan and China, where the incidence of breast cancer is one fifth of that in Western women, soy protein is a major dietary component. A Japanese prospective study found an inverse relationship between breast cancer risk and intake of miso soup, although a case-control study has failed to show a protective effect from soy intake [9] . A casecontrol study of Chinese women in Singapore found an inverse association between breast cancer risk and soy protein intake in premenopausal women [10] but a more recent Chinese study showed no such association [11] .
Isoflavones have a weak oestrogenic activity, but antioestrogenic properties are also reported [12] . Genistein at high concentration inhibits the growth of receptorpositive human breast cancer cell lines, although at lower concentrations growth is stimulated [13] . Isoflavones are thought to compete with oestradiol for binding to oestrogen receptor, and prolonged exposure decreases the response of cancer cells to oestrogen stimulation [14] .
A recent study in premenopausal women [15] reported that administration of soy milk supplements of over 200 mg isoflavone daily for one month caused reduction of serum oestradiol levels which persisted for two to three months after soy was withdrawn. On the other hand, an earlier study in premenopausal women [16] reported that soy supplements of 45 mg isoflavone daily caused a rise in oestradiol levels. It is possible that beyond a threshold intake, genistein may decrease ovarian aromatisation of androgen to oestrogen by inhibiting tyrosine kinases in ovarian follicular cells [17] .
Most studies assume that the antiproliferative effect of genistein in mammary cancer involves an effect on oestrogen bioactivity, but at high concentration it also inhibits the growth of oestrogen receptor-negative human breast cancer cell lines [13] . It has been shown to inhibit growth stimulation in these cells induced by insulin or insulin-like growth factor [14, 18] . Activity of these growth factors is mediated by IGF1 receptor tyrosine kinase activity and the cancerostatic effect of genistein may be exerted by blocking this process [18] . However, genistein's antioxidant properties may also contribute to its cancer-restraining effect in non hormone-related cancers [19] .
Many agents are competing for selection in human cancer chemoprevention trials. An agent that can be given orally, is free from any potential side effect and has compelling animal and laboratory evidence of cancerostatic properties should be given high priority. The safety of food derived from soybeans is assured by a history of its wide use for centuries in Asian populations. Allergic reactions to soy products are rare in adults. Although soy products may have a relatively low zinc, iron and calcium content, their incorporation into a well balanced diet should avoid problems [20] . An added advantage of soy protein is that it reduces blood lipid levels and has been shown effective in treating hypercholesterolaemia [21] . The mechanism and component of soy responsible for this effect is uncertain but may be related to the isoflavone content [22] .
Proposal for clinical study
Because of its confirmed effect on the mammary cancer model in rats and also on human mammary cancer cell lines, soy protein appears to be suitable for clinical trial to assess a possible effect in arresting or reversing breast cancer progression in the human. The first clinical trials could involve its long-term administration as adjuvant management after primary surgery in women with early breast cancer. Patients would be randomised into intervention and control groups, and compared for the incidence of recurrence and second primary breast cancer. The latter may provide evidence of a cancer-preventive effect as has been suggested in current adjuvant trials of tamoxifen and retinoid analogues in early breast cancer cases. Monitoring of weight, sex-steroid and metabolic parameters would be incorporated in the trial.
A clinical trial should aim at an isoflavone intake of at least 100 mg daily and this should not be difficult to achieve. Processing techniques have created a new generation of soy flour extracts with mild flavour and aroma, which can be incorporated into a wide variety of food products. These include mixtures of soy protein with cereals, dried milk or dried egg, apart from the traditional soy foods such as tofu and soy drinks which have the highest isoflavone content.
Conclusion
Further studies are required to investigate the effect of plant isoflavones on non-transformed mammary cells [7] , but there is enough evidence to warrant the setting up of trials of soy protein supplement as adjuvant treatment following primary surgery for early breast cancer. Not only is a diet containing soybean supplements completely safe and palatable, but in addition it would satisfy the desire of many patients to use a natural treatment and play an active role themselves in their fight against disease.
